273 related articles for article (PubMed ID: 23934770)
1. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
Melikian GL; Rhee SY; Varghese V; Porter D; White K; Taylor J; Towner W; Troia P; Burack J; Dejesus E; Robbins GK; Razzeca K; Kagan R; Liu TF; Fessel WJ; Israelski D; Shafer RW
J Antimicrob Chemother; 2014 Jan; 69(1):12-20. PubMed ID: 23934770
[TBL] [Abstract][Full Text] [Related]
2. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Reuman EC; Rhee SY; Holmes SP; Shafer RW
J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
[TBL] [Abstract][Full Text] [Related]
3. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
[TBL] [Abstract][Full Text] [Related]
4. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
[TBL] [Abstract][Full Text] [Related]
5. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
8. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
9. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
[TBL] [Abstract][Full Text] [Related]
11. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
12. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
13. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
[TBL] [Abstract][Full Text] [Related]
14. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
15. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY;
Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
17. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
[TBL] [Abstract][Full Text] [Related]
18. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
[TBL] [Abstract][Full Text] [Related]
20. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
Basson AE; Rhee SY; Parry CM; El-Khatib Z; Charalambous S; De Oliveira T; Pillay D; Hoffmann C; Katzenstein D; Shafer RW; Morris L
Antimicrob Agents Chemother; 2015 Feb; 59(2):960-71. PubMed ID: 25421485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
